Zafra H, Chiu AM. The changing face of the allergy/immunology fellowship, part 2: Death of the academic allergist? Ann Allergy Asthma Immunol. 2023 Sep;131(3):298-299 PMID: 37169326 SCOPUS ID: 2-s2.0-85160438067 05/12/2023
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E, ANDHI Study Investigators. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7 PMID: 36948488 SCOPUS ID: 2-s2.0-85152514359 03/23/2023
Jones D, Zafra H, Anderson J. Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor Journal of Asthma and Allergy. 2023;16:447-460 SCOPUS ID: 2-s2.0-85158155205 01/01/2023
Zafra H. Hereditary Angioedema: A Review. WMJ. 2022 Apr;121(1):48-53 PMID: 35442579 SCOPUS ID: 2-s2.0-85128793938 04/21/2022
Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, Martinez-Saguer I, Zanichelli A, Hao J, Inhaber N, Yu M, Riedl MA, HELP OLE Investigators. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy. 2022 Mar;77(3):979-990 PMID: 34287942 PMCID: PMC9292251 SCOPUS ID: 2-s2.0-85112680925 07/22/2021
Johnston DT, Busse PJ, Riedl MA, Maurer M, Anderson J, Nurse C, Inhaber N, Yu M, Banerji A, HELP Study Investigators. Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. Clin Exp Allergy. 2021 Oct;51(10):1391-1395 PMID: 34166549 PMCID: PMC9290609 SCOPUS ID: 2-s2.0-85113183008 06/25/2021
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021 Mar;9(3):260-274 PMID: 33357499 SCOPUS ID: 2-s2.0-85099581025 12/29/2020
Lumry WR, Weller K, Magerl M, Banerji A, Longhurst HJ, Riedl MA, Lewis HB, Lu P, Devercelli G, Jain G, Maurer M, HELP Study Investigators. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2021 Apr;76(4):1188-1198 PMID: 33258114 PMCID: PMC8247292 SCOPUS ID: 2-s2.0-85098010100 12/02/2020
Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH, Lu P, Hao J, Juethner S, Lumry WR, HELP Investigators. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020 Nov;75(11):2879-2887 PMID: 32452549 PMCID: PMC7689768 SCOPUS ID: 2-s2.0-85087498118 05/27/2020
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019 Jan;7(1):46-59 PMID: 30416083 SCOPUS ID: 2-s2.0-85056170947 11/13/2018